Palisade Bio Inc (NASDAQ: PALI) is 21.82% higher on its value in year-to-date trading and has touched a low of $1.38 and a high of $22.35 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PALI stock was last observed hovering at around $2.28 in the last trading session, with the day’s loss setting it -0.27%.
Currently trading at $2.01, the stock is 10.11% and -9.73% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.38 million and changing -11.84% at the moment leaves the stock -49.26% off its SMA200. PALI registered -74.84% loss for a year compared to 6-month loss of -55.03%. The firm has a 50-day simple moving average (SMA 50) of $2.2268 and a 200-day simple moving average (SMA200) of $3.9615.
The stock witnessed a 13.56% gain in the last 1 month and extending the period to 3 months gives it a -38.53%, and is 21.82% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 20.81% over the week and 18.99% over the month.
Palisade Bio Inc (PALI) has around 9 employees, a market worth around $5.56M and $0.00M in sales. Distance from 52-week low is 45.65% and -91.01% from its 52-week high. The company has generated returns on investments over the last 12 months (-212.85%).
The EPS is expected to grow by 55.67% this year
9.0 institutions hold shares in Palisade Bio Inc (PALI), with institutional investors hold 3.65% of the company’s shares. The shares outstanding are 2.77M, and float is at 2.72M with Short Float at 67.62%. Institutions hold 3.58% of the Float.
Palisade Bio Inc (PALI) Insider Activity
The most recent transaction is an insider purchase by Williams Donald Allen, the company’s Director. SEC filings show that Williams Donald Allen bought 1,000 shares of the company’s common stock on May 28 ’24 at a price of $4.86 per share for a total of $4863.0. Following the purchase, the insider now owns 1000.0 shares.
Palisade Bio Inc disclosed in a document filed with the SEC on May 24 ’24 that Finley John David (CEO, CFO, Director) bought a total of 1,000 shares of the company’s common stock. The trade occurred on May 24 ’24 and was made at $4.81 per share for $4810.0. Following the transaction, the insider now directly holds 8437.0 shares of the PALI stock.
Still, SEC filings show that on Feb 06 ’24, Finley John David (CEO, CFO, Director) acquired 10,000 shares at an average price of $0.47 for $4692.0. The insider now directly holds 84,649 shares of Palisade Bio Inc (PALI).
